What does Pinealon do?

Pinealon is identified as the synthetic tripeptide Glu-Asp-Arg, also called EDR. It is discussed within the Russian peptide-bioregulator literature and has been studied mainly for antioxidant and neuroprotective signals in laboratory models. The supplied evidence does not show randomized human clinical trials or FDA approval.

How does Pinealon work?

The proposed mechanism is that EDR may enter cells and influence gene-expression and protein-synthesis pathways. In neuronal and other cell models, the source reports reduced reactive oxygen species during oxidative stress, less apoptotic and necrotic cell death, and changes involving ERK 1/2 signaling and cell-cycle timing. These points remain preclinical hypotheses for human use.

Is Pinealon FDA approved?

No. The source lists Pinealon as not FDA approved and describes its clinical status as available in Russia but not approved by the FDA.

What side effects are reported for Pinealon?

The source lists headache, nausea, dizziness, vivid dreams, injection-site reactions, and caution in seizure disorders, while also describing it as generally well tolerated. The evidence provided does not include human safety datasets, so these entries should be treated as source-reported signals rather than quantified risks.

What dose is reported for Pinealon?

The source reports a community dose of 10-20 mg daily, typically once daily in the evening, and a research-literature entry of 10-20 mg daily over 10-30 day courses by oral or sublingual administration. This draft records source-reported dosing only and is not a recommendation.

Bioregulators Preclinical - animal studies only

Pinealon

Also known as: EDR, Glu-Asp-Arg

At a glance

PeptiGuide dataset · reviewed Aug 2026

What it is

Synthetic EDR tripeptide studied for preclinical neuroprotective and antioxidant signals.

Status

Preclinical

Evidence level: animal studies

Typical dose

10–20mg

Oral or sublingual

Researched for

Brain health, sleep, cognitive aging, neuroprotection

Trial progress

PrePreclinical
IPhase I
IIPhase II
IIIPhase III
IVPhase IV
FDAFDA approved

Preclinical - Promising animal research, limited human data

Use the tools

In plain language

Pinealon is a synthetic Glu-Asp-Arg tripeptide also known as EDR.
It is grouped with Russian bioregulators and is researched for brain health, sleep, cognitive aging, and neuroprotection.
The evidence described is , including cell-culture and animal work, with no supplied randomized human trial evidence.
Source-reported use lists 10-20 mg daily, often in the evening, by oral or sublingual administration.
It is listed as available in Russia and not FDA approved.

How it's thought to work

Pinealon/EDR is proposed to act as a short bioregulator with epigenetic effects on gene expression and protein synthesis. The supplied source reports that, in neuronal cell systems and related models, Pinealon reduced oxidative-stress-associated reactive oxygen species, lowered necrotic and apoptotic cell death, and affected ERK 1/2 signaling and cell-cycle timing. These mechanisms are not confirmed in human brain studies in the provided evidence.

What the research shows

Where the research stands

The supplied source places Pinealon in a evidence base centered on Russian -bioregulator research. Reported models include cultured cerebellar granule neurons, neutrophils, and PC12 cells, where Pinealon was associated with lower oxidative-stress ROS accumulation, reduced cell death, increased viability, and proliferative activity. Related EDR work is described in Alzheimer's-type and models, and the source notes overlap with Cortexin-related activity. The source also states that randomized human trials, human pharmacokinetic data, and human safety data were not available in the cited evidence.

What it shows

✓ Animal studies

Promising animal research, limited human data

△ Limitations

Animal study doses may not translate directly to humans.

Bottom line: Available in Russia - Not FDA approved Not FDA Approved

Typical dosing

CommunityCommunity dataset

10–20 mg

daily

10 mgfull range seen20 mg

Community-reported use describes Pinealon as part of the Khavinson peptide-bioregulator system with evening timing. This is not clinical dosing guidance.

Research dosing

Animal studies onlyAnimal studies only - may not translate to humans

Doses observed in studies

10-20 mg daily

Research Literature - Observed in studies

Animal study doses may not translate directly to humans.

Duration: 10-30 day courses
Administration: Oral or sublingual

Timing & administration

Best time to take

Evening or before bed

Once daily before bed

Food recommendation

With or without food

Why this timing?

The source links evening timing to Pinealon's proposed pineal-gland and sleep-regulation context, including melatonin timing. This is source-reported rationale, not validated clinical timing guidance.

Possible side effects

Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.

Generally well tolerated
Headache
Nausea
Dizziness
Vivid dreams
Injection site reactions
Caution with seizure disorders

Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.

Sources

PubMed ClinicalTrials.gov FDA.gov

Frequently asked questions

Sequence

H-Glu-Asp-Arg-OH (EDR)

One open dataset

Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.

Browse the dataset

Save to my research list Get updates on Pinealon

Educational resource, not medical advice. Talk to your clinician before acting on anything here.

Community discussion

Comments are moderated before they appear. Keep it evidence-focused.

Pinealon

In plain languageIn plain language

How it's thought to workHow it's thought to work

What the research showsWhat the research shows

Typical dosing

Research dosing

Timing & administrationTiming & administration

Possible side effectsPossible side effects

SourcesSources

Frequently asked questionsFrequently asked questions